(Q82493209)

English

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial

scientific article published on 13 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

6

object named as

Heinz Ludwig

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Carsten Bokemeyer

5

object named as

Carsten Bokemeyer

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Jean-Luc Canon

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Johan Vansteenkiste

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Michael Hedenus

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Pere Gascon

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jan Vermorken

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Jason Legg

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Beatriz Pujol

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Ken Bridges

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

13 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Medical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

2291-2299

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22081263%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

https://scigraph.springernature.com/pub.10.1007/s12032-011-0103-x

0 references

The rationale for pathogen-inactivation treatment of blood components.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer-related anemia: pathogenesis, prevalence and treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Perioperative blood transfusions and recurrence of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transfusion-related acute lung injury: a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fatigue in cancer patients compared with fatigue in the general United States population.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Symptomatology of anemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy-induced anemia in adults: incidence and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/22081263

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82493209&oldid=1985163252"